Bis‐Tetrahydrofuran: a Privileged Ligand for Darunavir and a New Generation of HIV Protease Inhibitors That Combat Drug Resistance
ChemMedChem2006Vol. 1(9), pp. 939–950
Citations Over TimeTop 10% of 2006 papers
Arun K. Ghosh, Perali Ramu Sridhar, Nagaswamy Kumaragurubaran, Yasuhiro Koh, Irene T. Weber, Hiroaki Mitsuya
Abstract
Two inhibitors that incorporate bis-THF as an effective high-affinity P2 ligand for the HIV-1 protease substrate binding site maintain impressive potency against mutant strains resistant to currently approved protease inhibitors. Crystallographic structures of protein–ligand complexes help to explain the superior antiviral property of these inhibitors and their potency against a wide spectrum of HIV-1 strains.
Related Papers
- → Decomposing the Energetic Impact of Drug Resistant Mutations in HIV-1 Protease on Binding DRV(2010)51 cited
- → Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir(2015)46 cited
- → Models of HIV-1 protease with peptides representing its natural substrates(1998)7 cited
- Investigation of Darunavir resistance against triple mutant (V32I, I47V and V82I) in HIV-1 protease by molecular simulation approach(2013)
- → Using substrate envelope to develop better HIV‐1 protease inhibitors.(2020)